Ondansetrom Azevedos (Ondansetron)

Ondansetron, the active ingredient in Ondansetrom Azevedos, is a 5‑HT3 receptor antagonist presented as a pharmaceutical product for oral use. It is employed to prevent and treat nausea and vomiting associated with chemotherapy, radiation therapy, and surgery in adult and pediatric patients.

GNH USA supplies Ondansetrom Azevedos as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ondansetron acts on the serotonin pathway to control nausea and vomiting in several clinical settings.

Chemotherapy‑induced nausea and vomiting: reduces the frequency and severity of nausea and vomiting in patients receiving cytotoxic chemotherapy. Post‑operative nausea and vomiting: prevents nausea and vomiting following surgical procedures. Radiation‑induced nausea and vomiting: alleviates nausea associated with therapeutic radiation exposure.

Common Side Effects: - Headache - Constipation - Dizziness - Fatigue - Diarrhoea - Abdominal discomfort

Serious or Rare Side Effects: - QT interval prolongation leading to cardiac arrhythmia - Severe allergic reactions including anaphylaxis - Serotonin syndrome when combined with other serotonergic agents - Marked hypotension - Hepatic enzyme elevations or liver injury - Extrapyramidal symptoms (rare).

Before initiating therapy, consider patient‑specific factors and monitor appropriately. - Cardiac assessment: evaluate baseline ECG and QT interval, especially in patients with known cardiac disease. - Hepatic function: use caution and consider dose adjustment in moderate to severe hepatic impairment. - Renal function: monitor renal status; dose may need adjustment in severe renal failure. - Concomitant QT‑prolonging drugs: avoid or use with heightened monitoring. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Ondansetron may interact with several medications; awareness of interaction severity guides clinical decisions.

Major Interactions (Avoid): - Apomorphine: co‑administration can cause severe hypotension and loss of consciousness. - Certain anti‑arrhythmics (e.g., quinidine, amiodarone): increase risk of QT prolongation. - Carbamazepine: induces metabolism, reducing ondansetron efficacy.

Moderate Interactions (Monitor Closely): - Aprepitant: may enhance anti‑emetic effect, requiring dose review. - Dexamethasone: potential additive effect on QT interval. - Fluoroquinolone antibiotics: modest increase in QT prolongation risk. - Tricyclic antidepressants: may modestly affect cardiac conduction. - Azole antifungals (e.g., ketoconazole): can increase ondansetron plasma levels.